Electra Therapeutics (ETRA) targets $342M IPO for drug trials

Electra Therapeutics plans to raise up to $341.9 million in an initial public offering (IPO) to fund Phase III development of its drug for hyperinflammatory syndrome. The company will offer 21,666,667 shares priced between $14 and $16 each, potentially raising $296.6 million if shares sell at the midpoint. Most of the IPO proceeds, about $220 million, will be allocated to advancing ipsoprubart through a Phase II/III trial for secondary hemophagocytic lymphohistiocytosis (sHLH). This matters for investors as the successful funding and development phases could lead to significant advancements in treatment options and potential market growth for Electra (ETRA).